Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

This publication has 25 references indexed in Scilit:

• Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)
  The Breast, 2019
• Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
  OncoTargets and Therapy, 2019
• Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
  BMC Cancer, 2013
• The determination and interpretation of the therapeutic index in drug development
  Nature Reviews Drug Discovery, 2012
• Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
  Cancer Chemotherapy and Pharmacology, 2011
• Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer
  Clinical Breast Cancer, 2010
• Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer
  Clinical Cancer Research, 2009
• The anti-angiogenic basis of metronomic chemotherapy
  Nature Reviews Cancer, 2004
• A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients
  Annals of Oncology, 2001
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989